IRAK-1-4 Inhibitor I NEW
| Price | $37 | $72 | $112 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: IRAK-1-4 Inhibitor I | CAS No.: 509093-47-4 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | IRAK-1-4 Inhibitor I |
| Description | IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4. |
| Cell Research | IRAK-1-4 Inhibitor I is dissolved in DMSO and stored, and then diluted with appropriate media before use[2]. NCM460 cells, grown in 24-well plates, are incubated with 50 μM IRAK-1/4 inhibitor for 2 h. After 2 h, the media are changed, and new media with or without LPS (10 ng/mL) added. Treatment is terminated at 6 h, and spent media and cells are collected for IL-8 and other assays[2]. |
| Kinase Assay | Kinase Assays: Cell-free kinase assays are done in quadruplicate with 1 μM ATP to determine the IC50 values of AV-951 against a variety of recombinant receptor and nonreceptor tyrosine kinases including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFRβ, Flt-3 and FGFR1. |
| In vitro | IRAK-1-4 Inhibitor I exhibits an IC50 greater than 10 μM against a panel of 27 kinases, including homologous kinases Lck and pp60SRC. It shows no cytotoxicity in a 72-hour proliferation assay in HeLa cells (ED50>30 μM). Significant inhibition of IRAK-1 is achieved with an IC50 of 0.3 μM[1]. IRAK-1/4 Inhibitor eliminates LPS-induced increases in Bcl10, NF-κB, and IL-8, with a 73% reduction in Bcl10 (from 5.18±0.22 to 2.36±0.08 ng/mL) and a 60% reduction in IL-8 (from 2.64±0.31 to 1.14±0.08 ng/mL)[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 8.13 mg/mL (20.55 mM), Sonication is recommended. |
| Keywords | IRAK | inhibit | IRAK-1-4 Inhibitor I | Interleukin-1 receptor associated kinase | IRAK 1 4 Inhibitor I | IRAK14 Inhibitor I | IL-1R associated kinase | Inhibitor |
| Inhibitors Related | IRAK inhibitor 2 | IRAK inhibitor 1 | IRAK4-IN-1 | IRAK-4 protein kinase inhibitor 2 | ANTHRAQUINONE-2-CARBOXYLIC ACID | Thalidomide 4-fluoride | IRAK4-IN-20 | GLPG2534 | Zabedosertib | Zimlovisertib | AS-2444697 | JH-X-119-01 |
| Related Compound Libraries | NF-κB Signaling Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/5Kg |
VIP1Y
|
SHANGHAI GEM CHEMICAL INDUSTRY CO.,LTD.
|
2024-12-23 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-25 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY